Merjaneh Nawal, Hajjar Mona, Lan Ying-Wei, Kalinichenko Vladimir V, Kalin Tanya V
Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA.
Department of Child Health, Division of Hematology and Oncology, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
Cancers (Basel). 2024 Feb 12;16(4):756. doi: 10.3390/cancers16040756.
Forkhead box M1 (FOXM1) is a transcription factor in the forkhead (FOX) family, which is required for cellular proliferation in normal and neoplastic cells. FOXM1 is highly expressed in many different cancers, and its expression is associated with a higher tumor stage and worse patient-related outcomes. Abnormally high expression of FOXM1 in cancers compared to normal tissue makes FOXM1 an attractive target for pharmacological inhibition. FOXM1-inhibiting agents and specific FOXM1-targeted small-molecule inhibitors have been developed in the lab and some of them have shown promising efficacy and safety profiles in mouse models. While the future goal is to translate FOXM1 inhibitors to clinical trials, potential synergistic drug combinations can maximize anti-tumor efficacy while minimizing off-target side effects. Hence, we discuss the rationale and efficacy of all previously studied drug combinations with FOXM1 inhibitors for cancer therapies.
叉头框M1（FOXM1）是叉头（FOX）家族中的一种转录因子，正常细胞和肿瘤细胞的增殖都需要它。FOXM1在许多不同的癌症中高表达，其表达与更高的肿瘤分期和更差的患者相关预后有关。与正常组织相比，FOXM1在癌症中的异常高表达使其成为药物抑制的一个有吸引力的靶点。实验室已开发出FOXM1抑制药物和特异性靶向FOXM1的小分子抑制剂，其中一些在小鼠模型中已显示出有前景的疗效和安全性。虽然未来的目标是将FOXM1抑制剂转化为临床试验，但潜在的协同药物组合可以在最大限度减少脱靶副作用的同时最大化抗肿瘤疗效。因此，我们讨论了所有先前研究的与FOXM1抑制剂联合用于癌症治疗的药物组合的基本原理和疗效。
